Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNA.
J Infect DisSep 23, 2026
Clinical ResearchInfectious Diseases
Tracy L Diamond, Anjana Grandhi, Monica Fuszard et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase III clinical trial evaluated the effects of baseline resistance-associated mutations (RAMs) on the virologic response to doravirine/islatravir (DOR/ISL) in 1227 virologically suppressed adults with HIV-1. At week 48, DOR/ISL maintained HIV-1 RNA <50 copies/mL in ≥88% of participants, regardless of the presence of baseline NNRTI RAMs or M184I/V mutations.
Key findings
- 26.3% of participants had baseline NNRTI RAMs.
- 5.7% of participants had baseline M184I/V mutations.
- DOR/ISL maintained HIV-1 RNA <50 copies/mL in ≥88% of participants at week 48.
- No treatment-emergent resistance to DOR or ISL was observed.
Why it matters
The findings suggest that doravirine/islatravir is effective in maintaining viral suppression in patients with HIV-1, even in the presence of specific resistance mutations, which is crucial for treatment planning.